摘要
Diosgenin, a steroidal sapogenin, obtained from Trigonella foenum-graecum, Dioscorea, and Rhizoma polgonati, has shown high potential and interest in the treatment of various cancers, such as oral squamous cell carcinoma, laryngeal cancer, esophageal cancer, liver cancer, gastric cancer, lung cancer, cervical cancer, prostate cancer, glioma, and leukemia. This article aims to provide an overview of the in vivo, in vitro,and clinical studies reporting the diosgenin’s anticancer effects. Preclinical studies have shown promising effects of diosgenin on inhibiting tumor cell proliferation and growth, promoting apoptosis, inducing differentiation and autophagy, inhibiting tumor cell metastasis and invasion, blocking cell cycle, regulating immunity and improving gut microbiome. Clinical investigations have revealed clinical dosage and safety property of diosgenin. Furthermore, in order to improve the biological activity and bioavailability of diosgenin, this review focuses on the development of diosgenin nano drug carriers, combined drugs and the diosgenin derivatives. However, further designed trials are needed to unravel the diosgenin’s deficiencies in clinical application.
基金
the National Natural Science Foundation of China(No.31860076)
Outstanding Young Talent Project of Zunyi Medical University(No.17zy-002)
Technology Support Program of Zunyi(No.ZSKH-HZ-ZI-2020-88)
Science and Technology Project of Zunyi[ZSKH-HZ(2020)No.60/55]
Special Project of Zunyi Medical University for Academic New Talents[No.QKHPT(2018)5772-067/062]
Guizhou Provincial Chinese Medicine Administration Project(No.QZYY-2019-064)。